BioSpace News Archive

Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, will display multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021.

- The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date April 9, 2021 Time 11:30 AM (EDT) Location

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021,

These important studies could one day lead to new cancer treatments and improved health equity — developments that will improve health outcomes for cancer patients everywhere

Systems Oncology, an AI-based pharmatech company, today announced that Dr. Spyro Mousses, CEO and Co-Founder of Systems Oncology, will present at the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery on Friday, April 16 th at 11.15 AM EST.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock sold by Outset and 3,444,859 shares of its common stock by certain of its stockholders at a public offering price of $53.50 per share.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR)

Intravenous administration could allow oncolytic viruses from Transgene’s Invir.IO™ platform to be used to treat a broad range of solid tumors

Growing mortality rate as a result of surging cancer cases is prompting manufacturers to develop advanced devices for early screening and detection